<DOC>
	<DOC>NCT01194804</DOC>
	<brief_summary>The objective of this study is to assess the long term safety of Eculizumab in hemolytic PNH patients who completed the 4 weeks screening and 12 weeks treatment period of C07-001 study. In addition, pharmacokinetic and pharmacodynamic assessments of Eculizumab will be conducted.</brief_summary>
	<brief_title>E07-001: Safety and Efficacy Extension Study of Eculizumab in Paroxysmal Nocturnal Hemoglobinuria Patients</brief_title>
	<detailed_description />
	<mesh_term>Hemoglobinuria, Paroxysmal</mesh_term>
	<mesh_term>Hemoglobinuria</mesh_term>
	<criteria>Patients must have fully completed C07001 study 12week treatment period Patients who terminated early from the C07001 study</criteria>
	<gender>All</gender>
	<minimum_age>12 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Hemolytic Paroxysmal Nocturnal Hemoglobinuria</keyword>
	<keyword>Eculizumab</keyword>
	<keyword>PNH</keyword>
</DOC>